Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Bacterial Communities Diverge in The Lower Airways of CF Children

By LabMedica International staff writers
Posted on 23 Dec 2021
Print article
Image: The EZ1 Advanced XL performs automated nucleic acid purification for a wide range of sample types relevant for molecular diagnostics, human identity testing, and gene expression analysis (Photo courtesy of Qiagen).
Image: The EZ1 Advanced XL performs automated nucleic acid purification for a wide range of sample types relevant for molecular diagnostics, human identity testing, and gene expression analysis (Photo courtesy of Qiagen).
Chronic airway infection and inflammation resulting in progressive, obstructive lung disease is the leading cause of morbidity and mortality in people with cystic fibrosis (CF). Culture-independent, molecular approaches have broadened the view from a few individual pathogens to more complex and dynamic polymicrobial communities.

In infants and young children with CF, culture-independent next-generation sequencing approaches have been useful in describing the upper airway microbiota, and previous studies have shown that younger patients have higher diversity which decreases as lung disease progresses. Longitudinal analysis of infant samples has identified changes in microbial composition and diversity in the first two years of life.

A team of Pulmonologists and Pediatricians, led by those at Lurie Children’s Hospital of Chicago (Chicago, IL, USA), and their colleagues evaluated clinical data and bronchoalveolar lavage fluid (BALF) samples from 191 participants up to age 21 years. Sixty-three patients had cystic fibrosis (mean age, 9.7 years; 65% female). DNA was extracted from BALF samples using the Qiagen EZ1 Advanced automated extraction platform (Qiagen, Valencia, CA, USA). Total bacterial load (TBL) was assessed using the quantitative PCR assay. Bacterial profiles were determined by amplification of the V1/V2 variable region (27F/338R) of the 16S rRNA gene. Operational taxonomic units (OTUs) were produced by clustering sequences with identical taxonomic assignments. Illumina paired-end sequencing was performed on the MiSeq platform using a 500-cycle version 2 reagent kit (Illumina, San Diego, CA, USA).

The investigators reported that higher bacterial load and lower microbial diversity in samples from patients with cystic fibrosis. In addition, these samples also had a divergence from disease controls aged 2 to 5 years and higher neutrophilic inflammation relative to bacterial burden, according to the results. They observed an increase in traditional cystic fibrosis pathogens and decreased Streptococcus mitis, S. oralis and S. pneumoniae species in the samples from older participants with cystic fibrosis. The most prevalent species-level taxa were S. mitis/oralis/pneumoniae (52%) and Prevotella melaninogenica (44%). There was increased diversity in the heterogeneous disease controls independent of cystic fibrosis diagnosis and indication.

Theresa Laguna, MD, MSCS, an Associate Professor of Pediatrics and senior author of the study, said, “Establishing key age-related differences in lower airway bacterial communities and inflammation in patients with CF, especially during early childhood, may give us a window of opportunity for earlier and more precise treatment. If we can prevent worse infections, we could improve the quality of life and potentially expand the life expectancy of patients with CF.”

The authors concluded that they had found distinctions between the airway microbiomes of CF and disease control subjects in a pediatric population that can inform future studies. By using 16S, they characterized complex polymicrobial communities in the lower airway from infancy up to young adulthood in people with and without CF. The study was published on October 6, 2021 in the journal PLOS ONE.

Related Links:
Lurie Children’s Hospital of Chicago
Qiagen
Illumina


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Coagulation Analyzer
CS-2400

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.